Expertise in
25
conditions

Dr. Anson K. Wurapa

Infectious Disease
Infectious Disease Specialists Of Atlanta
2665 North Decatur Road, Ste330, 
Decatur, GA 
32 Years of Experience
Referral may be required
Expertise in
25
conditions
Infectious Disease Specialists Of Atlanta
2665 North Decatur Road, Ste330, 
Decatur, GA 

Overview

Anson Wurapa is an Infectious Disease provider practicing medicine in Decatur, Georgia. He has been practicing medicine for over 32 years.

Dr. Wurapa is highly rated in 25 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.

Dr. Wurapa is board certified in American Board Of Internal Medicine, 2001. He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 4 clinical trials.

Graduate Institution

SUNY Upstate Medical University College Of Medicine, 1994.0

Residency

Case Western Reserve University/University Hospitals Cleveland Medical Center

Specialties

Infectious Disease

Licenses

Internal Medicine in GA

Board Certifications

American Board Of Internal Medicine, 2001

Fellowships

Strong Mem Hosp of The Univ of Rochester - NY

Hospital Affiliations

Emory Decatur Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Infectious Disease Specialists of Atlanta
2665 North Decatur Road, Ste330, Decatur, GA 30033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
Enrollment Status: Completed
Publish Date: May 30, 2024
Intervention Type: Drug
Study Drugs: Gepotidacin, Ceftriaxone, Azithromycin
Study Phase: Phase 3
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
Enrollment Status: Terminated
Publish Date: December 14, 2023
Intervention Type: Drug
Study Drugs: GSK3640254, Dolutegravir, Lamivudine
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
Enrollment Status: Completed
Publish Date: October 21, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

5 Total Publications

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.
Journal: HIV medicine
Published: December 20, 2024
Similar Doctors
Expertise in
10
conditions
Dr. Jesse Waggoner
Infectious Disease
Expertise in
10
conditions
Dr. Jesse Waggoner
Infectious Disease

Emory University Hospital Midtown Campus

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
 (16.4 miles away)
404-686-8114
Experience:
20+ years
Languages Spoken:
English
See accepted insurances

Jesse Waggoner is an Infectious Disease provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 20 years. Dr. Waggoner is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Dengue Fever, Viral Hemorrhagic Fever, Zika Virus Disease, and Togaviridae Disease. Dr. Waggoner is board certified in American Board Of Internal Medicine, 2012.

Expertise in
11
conditions
Dr. Monica Farley
Infectious Disease
Expertise in
11
conditions
Dr. Monica Farley
Infectious Disease

Department Of Veterans Affairs

1670 Clairmont Rd, 
Decatur, GA 
 (17.5 miles away)
404-321-6111
Languages Spoken:
English

Monica Farley is an Infectious Disease provider practicing medicine in Decatur, Georgia. Dr. Farley is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Strep Throat, Sepsis, Flu, and Necrotizing Fasciitis.

Expertise in
13
conditions
Dr. Kimberly A. Workowski
Infectious Disease
Expertise in
13
conditions
Dr. Kimberly A. Workowski
Infectious Disease

Emory University Hospital Midtown Campus

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
 (16.4 miles away)
404-686-8114
Experience:
40+ years
Languages Spoken:
English
See accepted insurances

Kimberly Workowski is an Infectious Disease provider practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 40 years. Dr. Workowski is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Syphilis, Hepatitis, and Gonorrhea. Dr. Workowski is board certified in American Board Of Internal Medicine, 1992.

Frequently Asked Questions about Dr. Anson K. Wurapa

How do I make an appointment with Dr. Anson K. Wurapa?

You can book an appointment with Dr. Anson K. Wurapa by calling their office at 404-297-9755. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anson K. Wurapa a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anson K. Wurapa is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anson K. Wurapa specialize in?

While Dr. Anson K. Wurapa is a Infectious Disease, they have specific expertise in HIV/AIDS, Myelitis, and AIDS Dementia Complex. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Anson K. Wurapa participate in research or clinical trials?

Yes. Dr. Anson K. Wurapa has published 5 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Anson K. Wurapa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anson K. Wurapa accept my insurance?

Dr. Anson K. Wurapa accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 404-297-9755 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wurapa's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile